Key Highlights

  • Scilex Holding (NASDAQ:SCLX) was trading down 47.45% at USD 0.66 on Tuesday, November 17, 2026, according to intraday market data, and no company announcement explaining the drop was found.
  • The latest 10-Q, for the quarter ended June 30, 2026, showed cash and equivalents of USD 0.6 million, down from USD 5.0 million at December 31, 2025.
  • Net Revenue for the second quarter was USD 7.6 million versus USD 9.9 million a year earlier, while the net loss was USD 115.0 million, largely from Fair Value losses.
  • Current Debt of USD 80.8 million plus USD 2.2 million of promissory notes comes to about USD 83.0 million (calculated), and noncurrent debt was nil.

A Steep Intraday Slide With No Announced Trigger

Scilex Holding (NASDAQ:SCLX) was trading at USD 0.66 on Tuesday, November 17, 2026, down 47.45% in the intraday screener data, which is the figure of record here. Searches of company releases and filings turned up no announcement dated November 14 to November 17 that explains the move, so no cause is stated. The company sells pain products, including ZTlido, ELYXYB and GLOPERBA, and is running a second Phase 3 study of SP-102 for sciatica that began in September 2025. Because the stock is a sub-USD 1 name, a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so the slide should not be read as a trend.

What the Latest 10-Q Shows: USD 0.6 Million of Cash

The most recent filing is the 10-Q for the quarter ended June 30, 2026. Second-quarter net revenue was USD 7.6 million against USD 9.9 million a year earlier, although six-month revenue rose to USD 16.3 million from USD 14.9 million. The net loss was USD 115.0 million for the quarter and USD 160.6 million for six months, with the filing attributing much of it to fair value losses on derivatives, digital Assets and Equity method investments. Cash and equivalents were USD 0.6 million, and marketable securities were USD 15 thousand. Scilex Holding (NASDAQ:SCLX) had 8,493,000 common shares outstanding on August 10, 2026, per the cover page; the count since then was not verified.

Debt, the ACEA Deal and What Could Still Matter

Current debt was USD 80.8 million and promissory notes USD 2.2 million, about USD 83.0 million combined (calculated), while noncurrent debt fell to nil from USD 22.5 million at year-end 2025. That shift moves obligations into the short term, which raises refinancing and dilution questions when cash is thin. On May 6, 2026 the company said subsidiaries ACEA Therapeutics and ACEA Pharma signed a stock Acquisition agreement with Nasdaq-listed Phoenix Asia Holdings, valued by the parties at USD 1.0 billion for 100 million new shares at USD 10.00, with closing expected by the end of the second quarter. Whether it closed was not verified. Scilex Holding (NASDAQ:SCLX) investors will watch the third-quarter 10-Q, any financing and any exchange notice.

Where Things Stand

No verified catalyst explains the 47.45% drop, so the answer rests on fundamentals. Scilex Holding (NASDAQ:SCLX) reported only USD 0.6 million of cash at June 30, 2026 against about USD 83.0 million of current debt and notes (calculated), and a quarterly net loss of USD 115.0 million. Thin Liquidity makes the stock sensitive to financing news, dilution and listing questions, and a sub-USD 1 quote can reverse quickly. Next markers are the third-quarter report, any Capital raise, an update on the ACEA transaction and any company statement about today's trading.